SCHEMBL365989

SCHEMBL365989

CCS(=O)(=O)NC(=O)c1ccc(Oc2cccc(F)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 4/20 0.50
MCL1 Q07820 4/20 0.50
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
SNCA P37840 1/20 0.46
GCK P35557 3/20 0.46
MGLL Q99685 1/20 0.45
MMP2 P08253 1/20 0.44
MMP3 P08254 1/20 0.44
MMP9 P14780 1/20 0.44
MMP14 P50281 1/20 0.44
MMP1 P03956 2/20 0.44
MMP13 P45452 1/20 0.44
P2RY14 Q15391 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
PGR P06401 1/20 0.42
HDAC3 O15379 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL678831 0.87 BCL2L1 (0.52) BCL2L1MCL1KDM4EALDH1A1SNCA
SCHEMBL363932 0.86 BCL2L1 (0.56) BCL2L1MCL1ALDH1A1MMP2MMP9
SCHEMBL365523 0.85 BCL2L1 (0.59) BCL2L1MCL1MMP2MMP9MMP1
SCHEMBL30147521 0.81 HPGD (0.67) KDM4EALDH1A1SNCAGCKMGLL
SCHEMBL29659751 0.81 HDAC1 (0.62) KDM4EALDH1A1NPC1RAB9A
SCHEMBL7983790 0.81 HDAC1 (0.62) KDM4EALDH1A1NPC1RAB9A
SCHEMBL680592 0.79 MMP13 (0.61) BCL2L1MCL1ALDH1A1MMP2MMP9
SCHEMBL16320154 0.78 MMP1 (0.57) BCL2L1MCL1KDM4EALDH1A1MMP1
SCHEMBL7987132 0.77 ALDH1A1 (0.50) ALDH1A1HDAC3RAB9A
SCHEMBL9937559 0.76 RAB9A (0.57) KDM4EALDH1A1MGLLP2RY14NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A BCL2L1 3284/4885MCL1 2739/4885KDM4E 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.